3 March 2010 Bevacizumab (Avastin) conjugated microbubbles for anti-VEGF treatment of neovascular age-related macular degeneration
Author Affiliations +
Proceedings Volume 7550, Ophthalmic Technologies XX; 75501P (2010); doi: 10.1117/12.841932
Event: SPIE BiOS, 2010, San Francisco, California, United States
Abstract
Bevacizumab (Avastin) has been used as one of the anti-VEGF therapies to manage neovascular age-related macular degeneration (AMD). The drug delivery system for bevacizumab needs to be improved in order to decrease the frequency of injection and reduce the adverse effects. In our study, bevacizumab was conjugated with poly (lactic-co-glycolic acid) (PLGA) microbubbles by activating carboxyl functional groups. The averaged size of microbubbles was estimated 1.055±0.258μm, allowing for ultrasound guided drug delivery. The binding efficiency between bevacizumab and microbubbles was evaluated in an enzyme-linked immunosorbent assay plate. The test results demonstrated the potential of using PLGA microbubbles to deliver bevacizumab with imaging guidance.
© (2010) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Leilei Zhang, Jeff Xu, Jiwei Huang, Cynthia Roberts, Ronald Xu, "Bevacizumab (Avastin) conjugated microbubbles for anti-VEGF treatment of neovascular age-related macular degeneration", Proc. SPIE 7550, Ophthalmic Technologies XX, 75501P (3 March 2010); doi: 10.1117/12.841932; https://doi.org/10.1117/12.841932
PROCEEDINGS
8 PAGES


SHARE
KEYWORDS
Therapeutics

Ultrasonography

Scanning electron microscopy

Laser scattering

Ophthalmology

Clinical trials

Luminescence

Back to Top